WO2023013498A1 - 新規フラビン依存性乳酸デヒドロゲナーゼ及び乳酸デヒドロゲナーゼの安定性を向上させる方法 - Google Patents

新規フラビン依存性乳酸デヒドロゲナーゼ及び乳酸デヒドロゲナーゼの安定性を向上させる方法 Download PDF

Info

Publication number
WO2023013498A1
WO2023013498A1 PCT/JP2022/028959 JP2022028959W WO2023013498A1 WO 2023013498 A1 WO2023013498 A1 WO 2023013498A1 JP 2022028959 W JP2022028959 W JP 2022028959W WO 2023013498 A1 WO2023013498 A1 WO 2023013498A1
Authority
WO
WIPO (PCT)
Prior art keywords
ldh
amino acid
seq
acid sequence
lactate dehydrogenase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2022/028959
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
遼太 鈴木
敦 一柳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kikkoman Corp
Original Assignee
Kikkoman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kikkoman Corp filed Critical Kikkoman Corp
Priority to US18/294,648 priority Critical patent/US20240401002A1/en
Priority to JP2023540286A priority patent/JPWO2023013498A1/ja
Priority to EP22852921.0A priority patent/EP4382608A4/en
Publication of WO2023013498A1 publication Critical patent/WO2023013498A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/02—Oxidoreductases acting on the CH-OH group of donors (1.1) with a cytochrome as acceptor (1.1.2)
    • C12Y101/02003—L-Lactate dehydrogenase (cytochrome) (1.1.2.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01027—L-Lactate dehydrogenase (1.1.1.27)

Definitions

  • the present invention provides a novel flavin-dependent lactate dehydrogenase (LDH), a nucleic acid encoding the same, a host cell having the nucleic acid, a method for producing LDH comprising culturing the host cell, and stability of the lactate dehydrogenase. about how to improve
  • LDH flavin-dependent lactate dehydrogenase
  • Lactate Blood lactate concentration and sweat lactate concentration are known as markers that reflect fatigue and physical condition. Lactate is a major metabolite and is recognized to be important for health assessment, including in critically ill and/or surgical patients, as well as indicators of health care. It can be an indicator for various pathological conditions such as disorders. Lactate monitoring can be used to detect sepsis, hypoxia, and the presence of cancerous tissue [1].
  • FMN-LDH FMN-dependent lactate dehydrogenase
  • Non-Patent Document 2 FMN-dependent lactate dehydrogenase
  • Enzymes that use lactic acid as a substrate include lactate oxidase (hereinafter, LOD), NAD-dependent lactate dehydrogenase (hereinafter, NAD-LDH) that uses nicotinamide dinucleotide (NAD) as a coenzyme, and flavin mononucleotide (FMN). ) is known as a coenzyme.
  • LOD lactate oxidase
  • NAD-LDH NAD-dependent lactate dehydrogenase
  • FMN flavin mononucleotide
  • LOD has the problem of generating hydrogen peroxide as a reaction product.
  • hydrogen peroxide which is a type of reactive oxygen species and a causative agent of oxidative stress
  • a sensor loaded with an enzyme there is a concern that it is not preferable to adopt a sensor loaded with an enzyme to obtain.
  • hydrogen peroxide produced by the action of LOD has an adverse effect on the stabilization of LOD itself, and as a means of avoiding the resulting decrease in LOD activity, a lactate sensor coexisting with catalase for the purpose of removing hydrogen peroxide has been proposed. (Patent Document 1).
  • NAD-LDH catalyzes an enzymatic reaction that does not generate hydrogen peroxide
  • the issue of hydrogen peroxide generation does not occur.
  • lactic acid and pyruvic acid react reversibly. Recruitment is difficult.
  • FMN-LDH also catalyzes an enzymatic reaction that does not produce hydrogen peroxide, the issue of hydrogen peroxide production does not arise.
  • it since there is no problem of reversible reaction, among the three enzymes mentioned above, it is considered to be the most promising as a practical enzyme for the purpose of monitoring lactic acid.
  • Non-Patent Document 2 FMN-LDH derived from Saccharomyces cerevisiae (Non-Patent Document 2) known so far has a problem in stability.
  • An object of the present invention is to search for a novel flavin-dependent LDH with excellent stability and to provide a method for improving the stability of LDH.
  • the present inventors searched for a novel flavin-dependent LDH with excellent stability, found a mutant LDH with improved stability, and completed the present invention.
  • the present invention includes the following aspects. (1) the following (i) to (iii): (i) the amino acid sequence shown in SEQ ID NO: 3; (ii) an amino acid sequence having 70% or more identity with the amino acid sequence shown in SEQ ID NO: 3, or (iii) 110 to 502 of SEQ ID NO: 3 when aligned with the amino acid sequence shown in SEQ ID NO: 3 has an amino acid sequence selected from amino acid sequences having 70% or more identity with the amino acid sequence shown in SEQ ID NO: 3 in the region of position 3, deletion of the N-terminus, and/or positions 54, 156, and 349
  • a lactate dehydrogenase comprising a mutation at one or more positions selected from the group consisting of positions 1 and 428.
  • (8) A host cell having the nucleic acid according to (7) above.
  • (9) A method for producing lactate dehydrogenase, comprising culturing the host cell according to (8) above.
  • a novel flavin-dependent LDH with excellent stability a nucleic acid encoding the same, a host cell having the nucleic acid, a method for producing LDH comprising culturing the host cell, and improved stability of LDH can provide a method.
  • FIG. 1 shows an alignment of the amino acid sequences of SEQ ID NO:3 and SEQ ID NO:5.
  • LDH LDH to which the present disclosure can be applied
  • LDH as used in the present invention is an enzyme that catalyzes the reaction of oxidizing the hydroxyl group of lactic acid to produce pyruvic acid in the presence of an electron acceptor, like known wild-type or mutant LDH.
  • the substrate of LDH is lactic acid, which may be provided as a mixture of L- and D-forms, such as a racemate, or may be provided as an L-form.
  • the LDH of the present invention has (i) an amino acid sequence represented by SEQ ID NO: 3, (ii) high identity with the amino acid sequence represented by SEQ ID NO: 3, for example, 70% or more, more preferably 75% or more, and more preferably 80% or more, more preferably 85% or more, more preferably 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, more preferably 95% or more, 96% or more, 97% or more, 98% % or more, most preferably 99% or more identity, or (iii) in the region from position 110 to 502 of SEQ ID NO: 3 when aligned with the amino acid sequence shown in SEQ ID NO: 3, the sequence High identity with the amino acid sequence represented by number 3, for example, 70% or more, more preferably 75% or more, still more preferably 80% or more, more preferably 85% or more, still more preferably 90% or more, 91% or more, Amino acid sequences selected from amino acid sequences having 92% or more, 93% or more
  • the LDH of the present invention has the N-terminus in SEQ ID NO: 3 at positions 2-3, 2-4, 2-5, 2-6, 2-7, 2-75, 2- Deletion at position 83, or positions 2-91.
  • the mutation at position 54 in LDH having the amino acid sequence shown in SEQ ID NO: 3 of the present invention is A54C
  • the mutation at position 156 is Y156F
  • the mutation at position 349 is Y349F
  • the mutation at position 428 is F428L.
  • a sequence having an amino acid sequence highly identical to SEQ ID NO: 3 may be, for example, the amino acid sequence shown in SEQ ID NO: 5.
  • the LDH of the present invention has the amino acid sequence shown in SEQ ID NO: 5 or has a high identity with it, for example, 70% or more, more preferably 75% or more, even more preferably 80% or more, still more preferably 85% or more, further preferably 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, more preferably 95% or more, 96% or more, 97% or more, 98% or more, most preferably 99% or more identity Any LDH having an amino acid sequence and containing an N-terminal deletion and/or mutation at position 52 in SEQ ID NO:5.
  • the LDH of the present invention has the N-terminus in SEQ ID NO: 5 at positions 2-3, 2-4, 2-5, 2-6, 2-7, 2-73, 2- Deletion at position 81, or positions 2-89.
  • the mutation at position 52 (corresponding to position 54 of SEQ ID NO: 3 in alignment with SEQ ID NO: 3) in LDH having the amino acid sequence shown in SEQ ID NO: 5 of the present invention is S52C.
  • the LDH of the present invention exhibits LDH activity only in the amino acid sequence at positions 110-502 of the amino acid sequence shown in SEQ ID NO:3. Therefore, it can be seen that the amino acid sequence at positions 110-502 of the amino acid sequence shown by SEQ ID NO: 3 is a region particularly important for the function (activity) of LDH.
  • the region particularly important for the function (activity) of LDH (the region corresponding to positions 110 to 502 of SEQ ID NO: 3) , 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, more preferably 95% or more with the amino acid sequence represented by SEQ ID NO: 3 % or more, 96% or more, 97% or more, 98% or more, or 99% or more of the amino acid sequence.
  • Amino acid sequence identity is determined by GENETYX Ver. 11 (manufactured by Genetics) programs such as maximum matching and search homology, or DNASIS Pro (manufactured by Hitachi Solutions) programs such as maximum matching and multiple alignment.
  • an alignment of the LDH shown in SEQ ID NO: 3 and another LDH was performed to identify positions corresponding to specific positions of the LDH of SEQ ID NO: 3 in the other LDH.
  • Positions 428 and 502 are respectively positions 3, 4, 5, 52, 73, 81, 89, 108, 154, 347, 426 and 500 of SEQ ID NO:5.
  • Amino acid sequence alignments can be performed using, for example, CLUSTALW and Blosum62 as an algorithm.
  • the present invention is a nucleic acid encoding the above LDH.
  • the present invention is a host cell having the above nucleic acid.
  • host cells There is no limitation on host cells as long as they are conventional cells used in the technical field.
  • Escherichia coli K-12 strain and its derivatives eg JM109 strain
  • Escherichia coli B strain and its derivatives eg BL21 strain
  • Bacillus subtilis eg Bacillus subtilis etc.
  • lactic acid bacteria eg Lactococcus lactis etc.
  • the present invention is a method for producing LDH, comprising culturing the host cell.
  • the present invention provides an amino acid sequence represented by SEQ ID NO: 3 or an amino acid sequence having high identity to it, for example, 70% or more, more preferably 75% or more, even more preferably 80% or more, further preferably 85% or more. % or more, more preferably 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, more preferably 95% or more, 96% or more, 97% or more, 98% or more, most preferably 99% LDH comprising the step of deleting the N-terminus and/or mutating one or more positions selected from the group consisting of positions 54, 156, 349 and 428 in the amino acid sequence having the above identity. It is a method to improve the stability of According to the present invention, LDH with improved stability can be produced.
  • the present invention provides an amino acid sequence represented by SEQ ID NO: 5 or a sequence having high identity to it, for example, 70% or more, more preferably 75% or more, even more preferably 80% or more, further preferably 85% or more. % or more, more preferably 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, more preferably 95% or more, 96% or more, 97% or more, 98% or more, most preferably 99%
  • a method for improving the stability of LDH comprising the steps of deleting the N-terminus and/or mutating position 52 in the amino acid sequence having the above identity. According to the present invention, LDH with improved stability can be produced.
  • a region particularly important for the function (activity) of LDH (corresponding to positions 110 to 502 of SEQ ID NO: 3) when aligned with the amino acid sequence shown in SEQ ID NO: 3 region), the amino acid sequence represented by SEQ ID NO: 3 or highly identical thereto, for example, 70% or more, more preferably 75% or more, more preferably 80% or more, more preferably 85% or more, more preferably has 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, more preferably 95% or more, 96% or more, 97% or more, 98% or more, and most preferably 99% or more identity N-terminal deletion and / or mutating one or more positions selected from the group consisting of positions 54, 156, 349 and 428 in the amino acid sequence having improved stability of LDH It is a method to let According to the present invention, LDH with improved stability can be produced.
  • LDH activity can be measured using this principle of action, for example, using the following measurement system using phenazine methosulfate (PMS) and 2,6-dichloroindophenol (DCIP) as electron acceptors.
  • PMS phenazine methosulfate
  • DCIP 2,6-dichloroindophenol
  • reaction 1 PMS (reduced form) is generated as L-lactic acid is oxidized.
  • reaction 2 DCIP is reduced as PMS (reduced form) is oxidized.
  • the degree of disappearance of this "DCIP (oxidized form)" is detected as the amount of change in absorbance at a wavelength of 520 nm, and the enzyme activity can be determined based on this amount of change.
  • LDH activity can be measured according to the following procedure. 170 ⁇ L of 1 M potassium phosphate buffer (pH 7.5), 300 ⁇ L of 50 mM DL-lactic acid solution, 250 ⁇ L of 1.8 mM DCIP solution and 680 ⁇ L of ultrapure water are mixed and incubated at 37° C. for 2 minutes or longer. 50 ⁇ L of 30 mM PMS solution and 50 ⁇ L of enzyme sample solution are then added to initiate the reaction. Absorbance is measured at the start of the reaction and over time, and the amount of decrease in absorbance at 520 nm per minute ( ⁇ A 520 ) accompanying the progress of the enzymatic reaction is determined, and the LDH activity is calculated according to Equation 1 below. At this time, 1 U of the LDH activity is defined as the amount of enzyme that reduces 1 ⁇ mol of DCIP per minute in the presence of L-lactic acid at a concentration of 10 mM at 37°C.
  • 1.5 is the liquid volume (mL) of the reaction reagent + enzyme reagent
  • 6.8 is the millimole molecular absorption coefficient (mM -1 cm -1 ) of DCIP under the activity measurement conditions
  • 0.05 is the enzyme Solution volume (mL)
  • 1.0 is the optical path length of the cell (cm)
  • ⁇ A 520 blank is 10 mM potassium phosphate buffer containing 0.15% (w/v) bovine serum albumin (pH 6.0 ) instead of the enzyme sample solution to initiate the reaction, the amount of decrease in absorbance at 520 nm per minute
  • Df represents the dilution factor.
  • the thermal stability of LDH can be evaluated by heating LDH at a predetermined temperature for a predetermined time and comparing the activity before and after heating. Specifically, a 150 mM potassium phosphate buffer (pH 7.5) containing 0.15% (w/v) bovine serum albumin as a final concentration containing LDH was allowed to stand on ice at a predetermined temperature (e.g., 45 C., 50.degree. C., 55.degree. C., 60.degree. Assuming that the LDH activity of the LDH solution left standing on ice without heat treatment is 100, the activity of the LDH solution after heating can be calculated, and the residual activity rate (%) can be measured.
  • a predetermined temperature e.g. 45 C., 50.degree. C., 55.degree. C., 60.degree.
  • Improved stability of LDH means not only “improved thermal stability in solution state”, but also “improved thermal stability in dry state”, or “improved thermal stability in drying process", Alternatively, it also includes “improved storage stability (long-term stability) in a solution state” and “improved storage stability (long-term stability) in a dry state”. That is, the term “improved stability” as used in the present disclosure means that the LDH-containing composition is coexistent with a specific stabilizer under constant temperature conditions, after heat treatment for a certain period of time, or after long-term storage. It refers to an increase in the residual activity rate (%) of maintained LDH as compared to before the mutation introduction.
  • the residual activity rate (%) is obtained by measuring the LDH activity value (a) of the solution before heat treatment or long-term storage and the LDH activity value (b) after heat treatment or after long-term storage. b)/(a) ⁇ 100).
  • the residual activity rate (%) of LDH after mutagenesis after heat treatment or after long-term storage is calculated, and this is designated as A.
  • the residual activity rate ( %) as B, and when A/B>1, it is evaluated that the stability of LDH is improved.
  • SEQ ID NO: 1 is the amino acid sequence of Pichia kudriavzevii-derived LDH (PkLDH), and 506 amino acids of Saccharomyces cerevisiae-derived LDH (ScLDH) shown in SEQ ID NO: 2 were compared, and positions 2 to 77 of SEQ ID NO: 1 were compared.
  • the 1509 bp gene shown in SEQ ID NO: 4 (including the stop codon TAA) encoding the removed 502 amino acids shown in SEQ ID NO: 3 was obtained as a double-stranded DNA by standard PCR of the gene fragment.
  • the 1503 bp gene (including the stop codon TAA) represented by SEQ ID NO: 6, which encodes 500 amino acids represented by SEQ ID NO: 5, was obtained as double-stranded DNA by standard PCR of the gene fragment. .
  • These genes were inserted into the multicloning site of plasmid pKK223-3 by a conventional method to obtain a recombinant plasmid pKK223-3-PkLDH.
  • this reaction solution is directly used to transform E. coli JM109. and developed on LB-100 ⁇ g/mL ampicillin (hereinafter referred to as Amp) agar medium.
  • Amp ampicillin
  • Ligation high Ver. 5.0 ⁇ L of 2 manufactured by Toyobo
  • 1.0 ⁇ L of 5 U/ ⁇ L T4 polyucleotid Kinase manufactured by Toyobo
  • 7.0 ⁇ L of sterilized water were added and allowed to react at 16° C. for 1 hour. Using.
  • the grown colony was added to 2.5 mL of LB-Amp medium [1% (w/v) bactotryptone, 0.5% (w/v) peptone, 0.5% (w/v) NaCl, 100 ⁇ g/mL Amp]. and cultured with shaking at 37° C. for 20 hours to obtain a culture. This culture was centrifuged at 15,000 rpm for 5 minutes to collect the cells. Next, the recombinant plasmid was extracted from the cells using FastGene Plasmid Mini Kit (manufactured by Nippon Genetics) and purified to obtain DNA.
  • FastGene Plasmid Mini Kit manufactured by Nippon Genetics
  • Escherichia coli strain JM109 or BL21 was used as an LDH-producing strain.
  • the transformed Escherichia coli JM109 or BL21 was previously cultured on an LB plate medium (containing 100 ⁇ g/mL Amp).
  • IPTG galactopyranoside
  • the culture solution was centrifuged at 7000 rpm and 4° C. for 5 minutes to remove the supernatant and collect the cells. Then, the obtained cells were suspended in 600 ⁇ L of 150 mM potassium phosphate buffer (pH 7.5).
  • the above cell suspension was subjected to ultrasonic disruption until the suspension became translucent, followed by centrifugation at 15,000 rpm and 4°C for 5 minutes. The supernatant was collected with care. The enzymatic activity was measured using this supernatant of the cell lysate (hereinafter referred to as "crude enzyme").
  • the stability of PkLDH is improved by comparing the residual activity rate (%) before and after mutagenesis of LDH according to the method for evaluating thermal stability of LDH described above.
  • a search for mutations was carried out.
  • the thermal stability of LDH was evaluated by heating LDH at a predetermined temperature for a predetermined time and comparing the activity before and after heating. Specifically, a 150 mM potassium phosphate buffer (pH 7.5) containing 0.15% (w/v) bovine serum albumin as a final concentration containing LDH was allowed to stand on ice for 15 minutes at 55°C. After heating, LDH activity was measured.
  • the LDH activity of the LDH solution left standing on ice without heat treatment was measured, and the activity of the LDH solution after heating was calculated as 100, and the residual activity rate (%) was measured. .
  • the residual activity rate (%) is obtained by measuring the LDH activity value (a) of the solution before heat treatment or long-term storage and the LDH activity value (b) after heat treatment or after long-term storage. It was calculated by calculating b)/(a) ⁇ 100).
  • the degree of the effect of improving the stability of LDH by introducing various mutations is determined by measuring the residual activity rate (%) of LDH after introduction of various mutations and comparing it with the residual activity rate (%) before mutation introduction.
  • the relative value of the residual activity rate of the enzyme after mutagenesis is calculated. and evaluated. For example, if the residual activity rate of the crude enzyme for comparison is 80% and the residual activity rate of the enzyme after mutation is 85%, the relative value of the residual activity is 1.06.
  • LDH activity was measured according to the following procedure. 170 ⁇ L of 1 M potassium phosphate buffer (pH 7.5), 300 ⁇ L of 50 mM L-lactic acid solution, 250 ⁇ L of 1.8 mM DCIP solution and 680 ⁇ L of ultrapure water were mixed and incubated at 37° C. for 2 minutes or longer.
  • 1.5 is the liquid volume (mL) of the reaction reagent + enzyme reagent
  • 6.8 is the millimole molecular absorption coefficient (mM -1 cm -1 ) of DCIP under the activity measurement conditions
  • 0.05 is the enzyme Solution volume (mL)
  • 1.0 is the optical path length of the cell (cm)
  • ⁇ A 520 blank is 10 mM potassium phosphate buffer containing 0.15% (w/v) bovine serum albumin (pH 6.0 ) instead of the enzyme sample solution to initiate the reaction, the amount of decrease in absorbance at 520 nm per minute
  • Df represents the dilution factor.
  • LDH solution (2-3 U/mL) containing 150 mM potassium phosphate buffer and 0.15% (w/v) bovine serum albumin (BSA) was used according to the method for evaluating thermal stability described above. A residual activity rate was calculated.
  • BSA bovine serum albumin
  • Table 2 shows the relative values of the residual activity rate of LDH containing the N-terminal deletion according to the present invention, with the residual activity rate of the wild-type PkLDH (comparative example) shown in SEQ ID NO: 3 being 1.
  • Table 3 also shows the residual activity ratio of LDH having F428L in wild-type PkLDH shown in SEQ ID NO: 3 (Invention 4) as 1, and the residual activity ratio of LDH containing the N-terminal deletion according to the present invention. Indicates a relative value.
  • Table 4 shows that the wild-type PkLDH shown in SEQ ID NO: 3 has F428L and the residual activity rate of LDH containing deletions at positions 2 to 3 (Invention 6) is set to 1, and further Y156F mutation and Y349F according to the present invention. The relative values of the residual activity rate of LDH containing the mutation and the F428L mutation are shown.
  • Fig. 1 shows the result of alignment of the amino acid sequences of SEQ ID NO: 3 and SEQ ID NO: 5.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Enzymes And Modification Thereof (AREA)
PCT/JP2022/028959 2021-08-03 2022-07-27 新規フラビン依存性乳酸デヒドロゲナーゼ及び乳酸デヒドロゲナーゼの安定性を向上させる方法 Ceased WO2023013498A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US18/294,648 US20240401002A1 (en) 2021-08-03 2022-07-27 Novel flavin-dependent lactate dehydrogenase and method for improving stability of lactate dehydrogenase
JP2023540286A JPWO2023013498A1 (https=) 2021-08-03 2022-07-27
EP22852921.0A EP4382608A4 (en) 2021-08-03 2022-07-27 NOVEL FLAVIN-DEPENDENT LACTATE DEHYDROGENASE AND METHOD FOR IMPROVING THE STABILITY OF LACTATE DEHYDROGENASE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-127638 2021-08-03
JP2021127638 2021-08-03

Publications (1)

Publication Number Publication Date
WO2023013498A1 true WO2023013498A1 (ja) 2023-02-09

Family

ID=85154538

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/028959 Ceased WO2023013498A1 (ja) 2021-08-03 2022-07-27 新規フラビン依存性乳酸デヒドロゲナーゼ及び乳酸デヒドロゲナーゼの安定性を向上させる方法

Country Status (4)

Country Link
US (1) US20240401002A1 (https=)
EP (1) EP4382608A4 (https=)
JP (1) JPWO2023013498A1 (https=)
WO (1) WO2023013498A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007075032A (ja) * 2005-09-15 2007-03-29 Oriental Yeast Co Ltd Ｄ−乳酸脱水素酵素
JP2018519507A (ja) 2015-06-15 2018-07-19 アボット ダイアベティス ケア インコーポレイテッドＡｂｂｏｔｔ Ｄｉａｂｅｔｅｓ Ｃａｒｅ Ｉｎｃ． 安定した乳酸応答性の酵素、電極およびセンサ並びにそれらの製造方法および使用方法
CN112813043A (zh) * 2021-02-23 2021-05-18 江南大学 一种酶活及稳定性提高的l-乳酸脱氢酶突变体及其应用
JP2021078427A (ja) * 2019-11-19 2021-05-27 アイシン精機株式会社 Ｄ−乳酸脱水素酵素変異体、ｄ−乳酸脱水素酵素変異体を備えたバイオ燃料電池、及び、バイオセンサ
WO2021167011A1 (ja) * 2020-02-21 2021-08-26 キッコーマン株式会社 検体の状態を評価するためのデバイス、それを含むシステム、検体の状態を評価する方法及びそれに用いる乳酸デヒドロゲナーゼ

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109906270A (zh) * 2016-09-16 2019-06-18 嘉吉公司 经遗传修饰的乳酸消耗酵母以及使用此类经遗传修饰的酵母的发酵工艺

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007075032A (ja) * 2005-09-15 2007-03-29 Oriental Yeast Co Ltd Ｄ−乳酸脱水素酵素
JP2018519507A (ja) 2015-06-15 2018-07-19 アボット ダイアベティス ケア インコーポレイテッドＡｂｂｏｔｔ Ｄｉａｂｅｔｅｓ Ｃａｒｅ Ｉｎｃ． 安定した乳酸応答性の酵素、電極およびセンサ並びにそれらの製造方法および使用方法
JP2021078427A (ja) * 2019-11-19 2021-05-27 アイシン精機株式会社 Ｄ−乳酸脱水素酵素変異体、ｄ−乳酸脱水素酵素変異体を備えたバイオ燃料電池、及び、バイオセンサ
WO2021167011A1 (ja) * 2020-02-21 2021-08-26 キッコーマン株式会社 検体の状態を評価するためのデバイス、それを含むシステム、検体の状態を評価する方法及びそれに用いる乳酸デヒドロゲナーゼ
CN112813043A (zh) * 2021-02-23 2021-05-18 江南大学 一种酶活及稳定性提高的l-乳酸脱氢酶突变体及其应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"The Japanese Guidelines for the Management of Sepsis 2016", PNAS, vol. 112, no. 37, 15 September 2015 (2015-09-15), pages 11642 - 11647
DATABASE UNIPROTKB ANONYMOUS : "A0A1Q2YEU1 · A0A1Q2YEU1_9ASCO", XP093032260, retrieved from UNIPROT *
DATABASE UNIPROTKB ANONYMOUS : "W1QKE8 · W1QKE8_OGAPD", XP093032258, retrieved from UNIPROT *
METHODS ENZYMOL., vol. 53, 1978, pages 238 - 56
See also references of EP4382608A4

Also Published As

Publication number Publication date
JPWO2023013498A1 (https=) 2023-02-09
EP4382608A1 (en) 2024-06-12
US20240401002A1 (en) 2024-12-05
EP4382608A4 (en) 2025-07-16

Similar Documents

Publication Publication Date Title
JP6093700B2 (ja) フラビン結合型グルコースデヒドロゲナーゼ、フラビン結合型グルコースデヒドロゲナーゼの製造方法、およびそれを用いたグルコース測定方法
JP6184326B2 (ja) 基質特異性が向上したフラビン結合型グルコースデヒドロゲナーゼ
JPH10243786A (ja) 改変型グルコース脱水素酵素
JP6526572B2 (ja) 熱安定性が向上したフラビン結合型グルコースデヒドロゲナーゼ
JPWO2010053161A1 (ja) 改変型フラビンアデニンジヌクレオチド依存性グルコースデヒドロゲナーゼ
JP6635913B2 (ja) 比活性が向上したフラビン結合型グルコースデヒドロゲナーゼ
US7479383B2 (en) Modified pyrroloquinoline quinone (PQQ) dependent glucose dehydrogenase excellent in substrate specificity
WO2023013498A1 (ja) 新規フラビン依存性乳酸デヒドロゲナーゼ及び乳酸デヒドロゲナーゼの安定性を向上させる方法
JP4946019B2 (ja) ジアホラーゼ活性を有する変異型タンパク質
JP5811521B2 (ja) フラビンアデニンジヌクレオチド依存性グルコースデヒドロゲナーゼの比活性を向上するための方法
WO2016076364A1 (ja) 基質特異性が向上したフラビン結合型グルコースデヒドロゲナーゼ
JP2004313180A (ja) 基質特異性または安定性に優れたピロロキノリンキノン（ｐｑｑ）依存性グルコースデヒドロゲナーゼ改変体
US5744342A (en) Protein having heat-resistant malate dehydrogenase activity
JP6476542B2 (ja) 変異型グルコース−６−リン酸脱水素酵素
JP2014097050A (ja) ジアホラーゼ
JP5311615B2 (ja) 化学修飾ポリオール脱水素酵素およびその製造方法
JP2012019756A (ja) フラビンアデニンジヌクレオチド依存性グルコースデヒドロゲナーゼを用いるグルコース測定方法
JP4816103B2 (ja) グリセロールキナーゼ改変体
JP5531272B2 (ja) 熱安定性を向上させた改変型グリセロールキナーゼ
JP2006081407A (ja) Ｐｑｑ依存性グルコースデヒドロゲナーゼの製造方法
JP2006034165A (ja) Ｐｑｑｇｄｈ製造法
JP6900652B2 (ja) 改変型ジアホラーゼ
JP4452988B2 (ja) ピロロキノリンキノン依存性グルコース脱水素酵素の比活性を向上する方法、および、比活性の向上したピロロキノリンキノン依存性グルコース脱水素酵素
JP4591074B2 (ja) 加熱処理を施した脱水素酵素
JP2006217811A (ja) 基質特異性に優れたピロロキノリンキノン（ｐｑｑ）依存性グルコースデヒドロゲナーゼ改変体

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22852921

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023540286

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022852921

Country of ref document: EP

Effective date: 20240304